Bacterial pneumonia

Revision as of 16:21, 24 January 2012 by WikiBot (talk | contribs)
Jump to navigation Jump to search

Template:DiseaseDisorder infobox

Pneumonia Main Page

Bacterial pneumonia Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Bacterial pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Bacterial pneumonia On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Bacterial pneumonia

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Bacterial pneumonia

CDC onBacterial pneumonia

Bacterial pneumonia in the news

Blogs on Bacterial pneumonia

to Hospitals Treating Bacterial pneumonia

Risk calculators and risk factors for Bacterial pneumonia

Editor(s)-in-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753; Philip Marcus, M.D., M.P.H.[2]

Overview

Bacterial pneumonia is an infection of the lungs by bacteria.

Streptococcus pneumoniae (J13) is the most common bacterial cause of pneumonia in all age groups except newborn infants. Streptococcus pneumoniae is a Gram-positive bacteria which often lives in the throat of people who do not have pneumonia. Another important Gram-positive cause of pneumonia is Staphylococcus aureus (J15.2).

Gram-negative bacteria are seen less frequently; Haemophilus influenzae (J14), Klebsiella pneumoniae (J15.0), Escherichia coli (J15.5), Pseudomonas aeruginosa (J15.1) and Moraxella catarrhalis are the most common. These bacteria often live in the gut and enter the lungs when contents of the gut (such as vomit) are inhaled.

The "atypical" bacteria are Coxiella burnetti, Chlamydophila pneumoniae (J16.0), Mycoplasma pneumoniae (J15.7), and Legionella pneumophila. They are "atypical" because they commonly affect teenagers and young adults, are less severe, and require different antibiotics than typical bacteria such as Streptococcus pneumoniae.

Pathophysiology

Bacteria typically enter the lung with inhalation, though they can reach the lung through the bloodstream if other parts of the body are infected. Often, bacteria live in parts of the upper respiratory tract and are continually being inhaled into the alveoli. Once inside the alveoli, bacteria travel into the spaces between the cells and also between adjacent alveoli through connecting pores. This invasion triggers the immune system to respond by sending white blood cells responsible for attacking microorganisms (neutrophils) to the lungs. The neutrophils engulf and kill the offending organisms but also release cytokines which result in a general activation of the immune system. This results in the fever, chills, and fatigue common in bacterial and fungal pneumonia. The neutrophils, bacteria, and fluid leaked from surrounding blood vessels fill the alveoli and result in impaired oxygen transportation.

The bacterium Streptococcus pneumoniae, a common cause of pneumonia, photographed through anelectron microscope.

Bacteria often travel from the lung into the blood stream and can result in serious illness such as septic shock, in which there is low blood pressure leading to damage in multiple parts of the body including the brain, kidney, and heart. They can also travel to the area between the lungs and the chest wall, called the pleural cavity.

Treatment

Antibiotics are the treatment of choice for bacterial pneumonia. The antibiotic choice depends on the nature of the pneumonia, the microorganisms most commonly causing pneumonia in the geographical region, and the immune status and underlying health of the individual. In the United Kingdom, amoxicillin is used as first-line therapy in the vast majority of patients who acquire pneumonia in the community, sometimes with added clarithromycin. In North America, where the "atypical" forms of community-acquired pneumonia are becoming more common, clarithromycin, azithromycin, or fluoroquinolones as single therapy, have displaced the amoxicillin as first-line therapy. Local patterns of antibiotic-resistance should always be considered when initiating pharmacotherapy. In hospitalized individuals or those with immune deficiencies, local guidelines determine the selection of antibiotics. These antibiotics are typically given through an intravenous line.

Treatment of gram-positive organisms

  • Streptococcus pneumoniae - amoxicillin (or erythromycin in patients allergic to penicillin); cefuroxime and erythromycin in severe cases.
  • Staphylococcus aureus - flucloxacillin (to counteract the organism's β-lactamase)

Treatment of gram-negative organisms

  • Haemophilus influenzae
  • Klebsiella pneumoniae
  • Escherichia coli
  • Pseudomonas aeruginosa
  • Moraxella catarrhalis

Treatment of atypical organisms

Most atypical causes of pneumonia require treatment for 14-21 days.

  • Chlamydophila pneumoniae - doxycycline
  • Chlamydophila psittaci - erythromycin
  • Mycoplasma pneumoniae - erythromycin
  • Coxiella burnetti - erythromycin
  • Legionella pneumophila - erythromycin, with rifampicin sometimes added.

People who have difficulty breathing due to pneumonia may require extra oxygen. An extremely sick individual may require artificial ventilation and intensive care as life-saving measures while his or her immune system fights off the infectious cause with the help of antibiotics and other drugs.

References

Template:WH Template:WS